Caredx's allosure lung dd-cfdna testing service receives medicare coverage for lung transplant rejection monitoring

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that caredx's allosure® lung donor-derived cell-free dna (dd-cfdna) molecular testing service has received medicare coverage. the moldx technology assessment program has determined that allosure lung will be covered under the exis.
CDNA Ratings Summary
CDNA Quant Ranking